[HTML][HTML] Comparison of the characteristics of uncommon epidermal growth factor receptor (EGFR) mutations and EGFR‑tyrosine kinase inhibitor treatment in patients …
Q Zhang, Y Cui, J Zhang… - Experimental and …, 2020 - spandidos-publications.com
Patients with epidermal growth factor receptor (EGFR)‑sensitive mutations generally have a
significantly higher objective response rate (ORR) and longer progression‑free survival …
significantly higher objective response rate (ORR) and longer progression‑free survival …
[HTML][HTML] Different efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer: a meta …
H Wang, J Huang, X Yu, S Han, X Yan, S Sun… - Journal of cancer …, 2014 - Springer
Background Nearly 85% of lung-cancer-specific epidermal growth factor receptor (EGFR)
sensitive mutations comprise a substitution at position 858 (21L858R) and deletion mutants …
sensitive mutations comprise a substitution at position 858 (21L858R) and deletion mutants …
[HTML][HTML] Overexpression of mutant EGFR protein indicates a better survival benefit from EGFR-TKI therapy in non-small cell lung cancer
Y Ling, X Yang, W Li, Z Li, L Yang, T Qiu, L Guo… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Background Epidermal growth factor receptor (EGFR) is a novel target for therapy in a
subset of non-small cell lung cancer (NSCLC). Tumors with EGFR mutations showed good …
subset of non-small cell lung cancer (NSCLC). Tumors with EGFR mutations showed good …
Outcomes of first-generation EGFR-TKIs against non-small-cell lung cancer harboring uncommon EGFR mutations: a post hoc analysis of the BE-POSITIVE study
S Pilotto, A Rossi, T Vavalà, A Follador, M Tiseo… - Clinical Lung Cancer, 2018 - Elsevier
Background Beyond progression after tyrosine kinase inhibitor in EGFR-positive non-small-
cell lung cancer patients (BE-POSITIVE) was the first Italian multicenter observational study …
cell lung cancer patients (BE-POSITIVE) was the first Italian multicenter observational study …
[HTML][HTML] Real-world clinical outcomes of first-generation and second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large cohort of …
A Pluzanski, M Krzakowski, D Kowalski… - ESMO open, 2020 - Elsevier
Background First-generation or second-generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitors (TKIs) are commonly used in EGFR-mutation-positive advanced …
tyrosine kinase inhibitors (TKIs) are commonly used in EGFR-mutation-positive advanced …
[HTML][HTML] Impact of EGFR mutation status on tumor response and progression free survival after first-line chemotherapy in patients with advanced non-small-cell lung …
Objectives Non-small-cell lung cancer (NSCLC) patients harboring sensitive epidermal
growth factor receptor (EGFR) mutations derive greater benefits from EGFR-tyrosine kinase …
growth factor receptor (EGFR) mutations derive greater benefits from EGFR-tyrosine kinase …
[HTML][HTML] A population-based study describing characteristics, survival and the effect of TKI treatment on patients with EGFR mutated stage IV NSCLC in the …
DMHJ Ten Berge, MJ Aarts, HJM Groen… - European Journal of …, 2022 - Elsevier
Introduction Since 2011, treatment guidelines advise targeted therapy (tyrosine kinase
inhibitor, TKI) for patients with activating epidermal growth factor receptor (EGFR) mutations …
inhibitor, TKI) for patients with activating epidermal growth factor receptor (EGFR) mutations …
[HTML][HTML] EGFR exon 18 mutations in advanced non-small cell lung cancer: A real-world study on diverse treatment patterns and clinical outcomes
H Xu, G Yang, W Li, J Li, X Hao, P Xing, Y Yang… - Frontiers in …, 2021 - frontiersin.org
Background Approximately 3%-5% of patients with epidermal growth factor receptor (EGFR)
mutation-positive non-small-cell lung cancer (NSCLC) harbor exon 18 mutations. The …
mutation-positive non-small-cell lung cancer (NSCLC) harbor exon 18 mutations. The …
Comparing the effectiveness of different EGFR‐TKIs in patients with EGFR mutant non–small‐cell lung cancer: a retrospective cohort study in Taiwan
YY Hsieh, WT Fang, YW Lo, YH Chen… - International journal of …, 2020 - Wiley Online Library
The study was to compare the effectiveness of different epidermal growth factor receptor—
tyrosine kinase inhibitors (EGFR‐TKIs) in patients with advanced non‐small‐cell lung …
tyrosine kinase inhibitors (EGFR‐TKIs) in patients with advanced non‐small‐cell lung …
[HTML][HTML] Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC …
JY Lee, X Qing, W Xiumin, B Yali, S Chi, SH Bak… - Oncotarget, 2016 - ncbi.nlm.nih.gov
We hypothesized that plasma-based EGFR mutation analysis for NSCLC may be feasible for
monitoring treatment response to EGFR TKIs and also predict drug resistance. Clinically …
monitoring treatment response to EGFR TKIs and also predict drug resistance. Clinically …